Tamoxifen resistance in breast cancer elucidating mechanisms
While about half of patients with advanced ER-positive disease immediately fail to respond to tamoxifen, in the responding patients the disease ultimately progresses to a resistant phenotype.
Overcoming tamoxifen resistance was a major topic at the 21st Annual San Antonio Breast Cancer Symposium [ San Antonio, US; December 1998 ].
Evidence was presented showing that the nature of tamoxifen itself may be the problem, as it has both estrogen-agonist and -antagonist properties. Although carefully collected, accuracy cannot be guaranteed. Differing provisions from the publisher's actual policy or licence agreement may be applicable.
The biological mechanisms underlying intrinsic () and acquired resistance to tamoxifen are therefore of considerable clinical significance.
Better understanding of these mechanisms may suggest novel strategies to overcome tamoxifen resistance and make further improvements in breast cancer survival.
Estrogen receptor (ER)-positive breast tumours are stimulated by estrogen, and so antiestrogenic therapy has become a fundamental adjuvant therapy for many women with this disease.